stockportfolio.pro
Stocks / ABT vs PFE
ABT vs PFE
Abbott Laboratories and Pfizer Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Abbott Laboratories (ABT) | Pfizer Inc. (PFE) | |
|---|---|---|
| Market cap | $154.4B | $148.2B |
| Revenue (latest FY) | $44.33B | $62.58B |
| Net income (latest FY) | $6.52B | $7.77B |
| Revenue growth (5y CAGR) | 5.1% | 8.5% |
| Net margin | 14.7% | 12.4% |
| Return on equity | 12.5% | 9.0% |
| P/E ratio | 24.7 | 19.8 |
| Dividend yield | 2.9% | 6.6% |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ABT — free Open PFE — freeFrequently asked questions
Which is bigger, ABT or PFE?
Abbott Laboratories is larger by market capitalization — $154.4B versus $148.2B.
Which grows faster, ABT or PFE?
Over the last five fiscal years, Pfizer Inc. grew revenue faster — 8.5%/yr versus 5.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.